SHP 623

Drug Profile

SHP 623

Alternative Names: rC1-INH - Shire; Recombinant-C1-esterase-Shire; SHP623

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire
  • Class Complement C1 inactivator proteins; Recombinant proteins
  • Mechanism of Action Complement C1 inhibitors; Complement system protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hereditary angioedema

Most Recent Events

  • 01 Dec 2016 Shire completes a phase I trial in Hereditary angioedema (In volunteers) in USA (SC and IV) (NCT02663687)
  • 01 Feb 2016 Phase-I clinical trials in Hereditary angioedema (In volunteers) in USA (SC and IV) (NCT02663687)
  • 01 Jan 2016 Preclinical trials in Hereditary angioedema in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top